Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.
2.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
3.
4.

[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].

Tang CH, Liu XQ, Gao HJ, Li JJ, Guo WF, Li XY, Wang WX, Liu B, Qu LL, Wang WW.

Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):143-7. Chinese.

PMID:
20403247
5.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.

PMID:
21684626
6.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.

PMID:
21223694
7.

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.

Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC.

Cancer Chemother Pharmacol. 2010 May;65(6):1023-8. doi: 10.1007/s00280-009-1107-5. Epub 2009 Aug 13.

9.

Gefitinib therapy for non-small cell lung cancer.

Birnbaum A, Ready N.

Curr Treat Options Oncol. 2005 Jan;6(1):75-81. Review.

PMID:
15610717
10.

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.

Lin CC, Yang CH.

Target Oncol. 2009 Jan;4(1):37-44. doi: 10.1007/s11523-009-0104-2. Epub 2009 Jan 20. Review.

PMID:
19343300
11.

Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F.

J Cell Physiol. 2005 Dec;205(3):355-63. Review.

PMID:
15895392
12.

Erlotinib in non-small cell lung cancer treatment: current status and future development.

Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F.

Oncologist. 2007 Jul;12(7):840-9. Review.

13.

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R.

Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11.

PMID:
20705357
14.
15.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.

Lung Cancer. 2009 Jul;65(1):80-4. doi: 10.1016/j.lungcan.2008.10.016. Epub 2008 Dec 6.

PMID:
19059670
16.

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.

Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC, Shih JY, Yang PC.

Lung Cancer. 2011 May;72(2):205-12. doi: 10.1016/j.lungcan.2010.08.013. Epub 2010 Sep 15.

PMID:
20832137
17.

A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA.

Lung Cancer. 2006 Jan;51(1):115-21. Epub 2005 Sep 26.

PMID:
16188343
18.

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.

Wu YL, Kim JH, Park K, Zaatar A, Klingelschmitt G, Ng C.

Lung Cancer. 2012 Aug;77(2):339-45. doi: 10.1016/j.lungcan.2012.03.012. Epub 2012 Apr 10.

PMID:
22494567
19.

Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.

Stepanski EJ, Houts AC, Schwartzberg LS, Walker MS, Reyes CM, Blakely J.

Clin Lung Cancer. 2009 Nov;10(6):426-32. doi: 10.3816/CLC.2009.n.080.

PMID:
19900861
20.

Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.

Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.

Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4.

PMID:
22760226

Supplemental Content

Support Center